Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101)

Recently, the stabilization of the endothelium has been explicitly identified as a therapeutic goal in coronavirus disease 2019 (COVID-19). Adrecizumab (HAM8101) is a first-in-class humanized monoclonal anti-Adrenomedullin (anti-ADM) antibody, targeting the sepsis- and inflammation-based vascular an...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Biomolecules
Päätekijät: Karakas, Mahir, Jarczak, Dominik, Becker, Martin, Roedl, Kevin, Addo, Marylyn M., Hein, Frauke, Bergmann, Andreas, Zimmermann, Jens, Simon, Tim-Philipp, Marx, Gernot, Lütgehetmann, Marc, Nierhaus, Axel, Kluge, Stefan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7465983/
https://ncbi.nlm.nih.gov/pubmed/32796765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biom10081171
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia